In 2021, AcouSort AB (publ) (”AcouSort”, “the Company”) received funding from Vinnova for the project IndiCell. The aim of the project is to enable the transfer of novel stem cell treatments from research to a clinical setting. The project is planned to run over five years and generate revenues of SEK 1.25 million to AcouSort. AcouSort has now finalized the application development and has installed an AcouTrap system at Karolinska Institutet, where it will be used to automate the isolation and wash of stem cells.
As part of the project, AcouSort has developed methods on the AcouTrap system for isolation and wash of stem cells before they are used in injections. The application development part is now finalized, and as part of the project an AcouTrap system has been installed at Karolinska Institutet, one of the consortium partners. The system will be used throughout the rest of the project to automate the isolation and wash of stem cells used in the research efforts to develop new stem cell-based therapies.
“The IndiCell project is a great example of how the AcouTrap can be used to automate cell sample preparation workflows and we are very happy to see how the recent update of AcouTrap has proven to be valuable in the development of new stem cell-based therapies,” says AcouSort’s Commercial Director Agnes Michanek.
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
E-mail: [email protected]
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company’s products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company’s products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company’s commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company’s research instruments. With the help of the company’s products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank.